Spyre Therapeutics, Inc. SYRE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $190.44M+12.4% | $171.65M+5.4% | $177.5M+21.6% | $176.99M+40.6% | $169.49M+53.2% | ||
| $51.2M+14.1% | $47.91M+4.7% | $46.15M-6.0% | $45.15M-4.0% | $44.87M-5.7% | ||
| $201.64M-5.9% | $209.56M+0.5% | $213.64M+10.6% | $212.15M+35.8% | $214.36M-21.2% | ||
| $201.64M-5.9% | $209.56M+0.5% | $213.64M+10.6% | $212.15M+35.8% | $214.36M-21.2% | ||
| -$201.64M+5.9% | -$209.56M-0.5% | -$213.64M-10.6% | -$212.15M-35.8% | -$214.36M+21.0% | ||
| $25.39M+8.6% | $24.89M+16.8% | $23.52M+19.6% | $23.33M+48.3% | $23.37M+130% | ||
| $27.56M+408% | $59.7M+9,867% | $64.66M+399% | $5.34M+118% | $5.43M+106% | ||
| $40M— | $10M— | $10M+443% | $10M-39.2% | $0— | ||
| -$179.44M+14.1% | -$155.22M+25.4% | -$148.98M+30.7% | -$206.81M-11.2% | -$208.93M+42.6% | ||
| $0-100% | -$15K-129% | -$14K-128% | $4K-88.6% | $4K-90.5% | ||
| -$179.44M+14.1% | -$155.2M+25.4% | -$148.97M+30.7% | -$206.81M-11.2% | -$208.93M+42.6% | ||
| -$2.12+30.7% | -$1.98+37.7% | -$1.48— | -$2.69— | -$3.06— | ||
| -$2.12+30.3% | -$1.98+37.3% | -$2.03— | -$2.94— | -$3.04— | ||
| 263.4M+29.4% | 245.1M+36.3% | 228M+63.3% | 218.5M+135% | 203.5M+295% | ||
| 263.4M+29.4% | 245.1M+36.3% | 228M+63.3% | 218.5M+135% | 203.5M+295% | ||
| $40M— | $10M— | $10M+443% | $10M-39.2% | $0— | ||
| $25.39M+8.6% | $24.89M+16.8% | $23.52M+19.6% | $23.33M+48.3% | $23.37M+130% | ||
| —— | —— | $41.14M+200% | -$17.99M+10.7% | -$17.94M+8.2% | ||
| $190.44M+12.4% | $171.65M+5.4% | $177.5M+21.6% | $176.99M+40.6% | $169.49M+53.2% | ||
| -$201.64M+5.9% | -$209.56M-0.5% | -$213.64M-10.6% | -$212.15M-35.8% | -$214.36M+21.0% | ||
| —— | -$209.56M-0.5% | -$213.64M— | -$212.15M— | -$214.36M— | ||
| -$201.64M+5.9% | -$209.56M-0.5% | -$213.64M-10.6% | -$212.15M-35.8% | -$214.36M+21.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Spyre Therapeutics, Inc. profitable?
- Spyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $179.4M over the trailing twelve months, a -52939.7% net margin.
- What is Spyre Therapeutics, Inc.'s earnings per share?
- Spyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.12.
- Where does Spyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.